Boston University Clinical and Translational Science Institute

波士顿大学临床与转化科学研究所

• 批准号: 10733148
• 负责人: MEGAN H BAIR-MERRITT
• 金额: $ 9.21万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-13 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10733148
• 关键词: Acetylation; Acute Myelocytic Leukemia; Address; Advocate; Amines; Autophagocytosis; Basic Science; Biochemical; Biological; Biophysics; Black Populations; Boston; Caring; Cell Proliferation; Cells; Clinical Research; Clinical Sciences; Collaborations; Communities; DNA Modification Methylases; Diagnostic; Disadvantaged; Disease; Disparity population; Double Minutes; Environment; Funding; Goals; Grant; HERC1 gene; Health; Health system; Healthcare; Healthcare Systems; Hematologic Neoplasms; Hispanic; Hispanic Populations; Individual; Inequity; Informatics; Lead; Learning; Longevity; Lysine; Malignant Neoplasms; Methods; Minority; Modification; Molecular; Molecular Probes; Multiple Myeloma; Mus; National Center for Advancing Translational Sciences; New England; Not Hispanic or Latino; Oncoproteins; Participant; Patients; Persons; Phosphorylation; Policy Maker; Positioning Attribute; Principal Investigator; Process; Property; Proteins; Proteomics; Provider; Public Policy; Recording of previous events; Research; Resources; Risk; Role; Site; Special Population; TP53 gene; Testing; Therapeutic Intervention; Training; Translational Research; Tumor Suppressor Proteins; Ubiquitin; Ubiquitination; Universities; Urban Population; Vision; career development; cell growth; drug discovery; empowerment; ethnic disparity; ethnic diversity; experience; experimental study; health care disparity; health disparity; health equity promotion; human disease; improved; inhibitor; innovation; leukemia; low socioeconomic status; mortality; multidisciplinary; new therapeutic target; novel; novel strategies; novel therapeutics; parent grant; patient population; programs; protein protein interaction; racial disparity; racial diversity; racial health disparity; research and development; synthetic protein; targeted treatment; tool; ubiquitin isopeptidase; ubiquitin-protein ligase; ubiquitin-specific protease

SUMMARY 1. Summary of the funded parent grant (BU CTSI) The overall theme of the Boston University Clinical and Translational Science Institute (BU CTSI) is to explore and solve major challenges in translational science, especially those that address the special health problems of disadvantage individuals from urban at risk communities by developing and deploying new tools, methods and processes to expedite clinical research in our hub and nationalize shared unique resources with the CTSA Network. To do this we will exploit our strengths in developing multi-disciplinary, multi-cultural collaborative teams across diverse programs. This approach follows on the BU CTSI’s history of actively engaging in continuous and vigorous dialogue within its own hub, with other CTSA hubs, and with NCATS to identify opportunities to catalyze clinical and translational research locally and nationally. Our goals are: Goal 1. Discover, demonstrate, deploy and disseminate novel programs to develop our entire translational science workforce. Goal 2. Further enhance our robust translational science environment to encourage all aspects of translational research, from scientific discovery to an efficient clinical research enterprise, exploiting our strengths in basic and clinical science, and in so doing address the health disparities of our at risk diverse patients and make the lessons learned and resources developed from our partners and affiliates available to the CTSA network. Goal 3. Effect meaningful multi-directional relationships among all our community stakeholders (patients, providers, purchasers, payers, public policy makers/advocates, product makers and principal investigators) to strengthen collaborative translational research across the lifespan of our special populations and enable novel approaches to integrating research into health care in our ACO. Goal 4. In collaboration with other CTSA Hubs, discover, develop and disseminate innovative tools, methods and programs to improve research on treatments and diagnostics that address our local and national health problems. Goal 5. Develop and demonstrate novel informatics innovations to Improve local Hub translational research in our unique learning health system and disseminate these innovations to the CTSA Network. The BU CTSI’s vision is to be the strongest possible advocate for, and participant in, translational research that serves the health needs of our diverse at risk URG patient populations by empowering our community and creating unique resources that can be integrated with and distributed to the national CTSA network.

总结 1.资助父母补助金摘要（BU CTSI） 波士顿大学临床和转化科学研究所（BU CTSI）的总体主题是 探索和解决转化科学的主要挑战，特别是那些解决特殊问题的挑战。 城市高危社区弱势群体的健康问题， 部署新的工具、方法和流程，以加快我们中心的临床研究， 与CTSA网络共享独特资源。为此，我们将利用我们的优势， 跨不同项目的多学科、多文化协作团队。此方法在BU上遵循 CTSI在自己的中心内积极参与与其他CTSA的持续和积极对话的历史 中心，并与NCATS，以确定机会，催化临床和转化研究本地和 全国范围内。我们的目标是： 目标1.发现，展示，部署和传播新的计划，以发展我们的整个翻译 科学劳动力。 目标2.进一步加强我们强大的翻译科学环境，以鼓励翻译的各个方面， 研究，从科学发现到高效的临床研究企业，利用我们在基础研究领域的优势， 和临床科学，并在这样做解决我们的风险不同的患者的健康差距， 从我们的合作伙伴和附属机构获得的经验教训和资源可供CTSA网络使用。 目标3.在我们所有的社区利益相关者（患者， 供应商、购买者、付款人、公共政策制定者/倡导者、产品制造者和主要研究者）， 在我们特殊人群的整个生命周期中加强合作转化研究， 将研究纳入我们ACO的医疗保健的方法。 目标4.与其他CTSA中心合作，发现、开发和传播创新工具、方法 以及改善治疗和诊断研究的计划，以解决我们的地方和国家健康问题 问题 目标5.开发和展示新的信息学创新，以改善当地中心的翻译研究， 我们独特的学习健康系统，并将这些创新传播到CTSA网络。 BU CTSI的愿景是成为转化研究的最强有力的倡导者和参与者， 通过赋予我们的社区权力，满足我们多样化的高危URG患者人群的健康需求， 创建可以与国家CTSA网络集成并分发给国家CTSA网络的独特资源。